Omada Health’s GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss

Rhea-AI Summary

Omada Health (Nasdaq: OMDA) released a 12-month real-world analysis of 965 members in its Enhanced GLP-1 Care Track showing durable weight loss when behavioral support is paired with GLP-1 medications. Members who persisted on medication for 12 months averaged 18.4% weight loss, versus 11.9% in cited real-world evidence; overall program members averaged 16.3% weight loss. Persistence at one year was 67%, higher than the 47–49% comparator. The analysis used pharmacy claims and clinical data and highlights Omada’s prescription and medication-management capability for anti-obesity medications.

Positive

• Average weight loss of 18.4% at 12 months for members who persisted on GLP-1s
• Overall program average weight loss of 16.3% across all members at 12 months
• Medication persistence of 67% at one year, above 47–49% in comparable study

Negative

• GLP-1 use was self-reported by members, which can introduce reporting bias
• Analysis is observational real-world data without reported randomized control, limiting causal claims

Key Figures

Avg weight loss persistent users 18.4% Members in GLP-1 companion program persisting 12 months

Real-world comparator weight loss 11.9% Published real world evidence benchmark at one year

Avg weight loss all members 16.3% All program members, regardless of GLP-1 persistence over 12 months

Sample size 965 members Omada members without diabetes in Enhanced GLP-1 Care Track

Medication persistence rate 67% Members remaining on GLP-1 medications through one year

Semaglutide added benefit 47% greater weight loss Omada members on semaglutide vs published real-world evidence

Tirzepatide added benefit 37% greater weight loss Omada members on tirzepatide vs published real-world evidence

Weight loss after discontinuation 13.1% Members who discontinued medication before one year

Market Reality Check

$15.41 Last Close

Volume Volume 1,017,214 vs 20-day average 927,360 (relative volume 1.1x) ahead of this announcement. normal

Technical Price $16.57 is trading below the 200-day MA of $19.92, and 41.65% below the 52-week high.

Peers on Argus 1 Up

OMDA was up 3.3% with slightly elevated volume, while key peers were mixed: SDGR up 1.13%, OMCL up 0.83%, but TDOC and GDRX down. Only OMCL showed momentum scanner strength, suggesting a stock-specific setup rather than a broad sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 22	Conference participation	Neutral	+6.8%	Announcement of J.P. Morgan Healthcare Conference participation and webcast details.
Nov 20	Conference participation	Neutral	-4.9%	Notice of Evercore Healthcare Conference fireside chat and webcast availability.
Nov 06	Earnings update	Positive	-6.1%	Strong Q3 revenue and membership growth with improved margins and raised guidance.
Nov 06	Product expansion	Positive	-6.1%	Launch of nationwide GLP-1 prescribing capability and highlighting superior weight outcomes.
Nov 04	Clinical data conference	Positive	-1.2%	ObesityWeek posters with real-world GLP-1 persistence and post-discontinuation weight data.

Pattern Detected

Recent history shows several positive or growth-focused announcements followed by flat-to-negative price reactions, especially around GLP-1 and earnings updates, indicating a tendency for the stock to sell off or underperform after good fundamental news.

Recent Company History

Over the last few months, OMDA has highlighted strong operating momentum and GLP-1–related initiatives. Q3 2025 results on Nov 6 showed rapid revenue and membership growth plus improved profitability, alongside a new GLP-1 prescribing offering. The company also presented real-world GLP-1 evidence at ObesityWeek 2025 on Nov 4–5, and announced participation in major conferences such as Evercore and the 44th J.P. Morgan Healthcare Conference. Today’s GLP-1 companion outcomes update extends this real-world evidence narrative and reinforces the same strategic focus on behavior-supported medication use.

Market Pulse Summary

This announcement extends Omada’s real-world GLP-1 evidence, with one-year weight loss of 18.4% for persistent users and 16.3% across all members, plus a 67% medication persistence rate. These outcomes build on prior ObesityWeek and Q3 updates that emphasized GLP-1 integration and behavior change. Investors may track future earnings, membership growth, and additional GLP-1 data releases to see how effectively these clinical results translate into scalable, durable business performance.

Key Terms

glp-1 medical

"Omada’s program paired with GLP-1 medications leads to greater weight loss"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

semaglutide medical

"47% greater average weight loss on semaglutide and 37% greater weight loss"

Semaglutide is a medication originally developed to help manage blood sugar levels in people with diabetes, but it also promotes weight loss. It works by mimicking a natural hormone that helps control appetite and insulin release. For investors, its potential to influence healthcare and weight management markets makes it a significant product in the pharmaceutical industry.

tirzepatide medical

"47% greater average weight loss on semaglutide and 37% greater weight loss on tirzepatide"

Tirzepatide is a prescription medicine that helps lower blood sugar and reduce appetite by activating two hormones that regulate insulin and hunger; think of it as a two-in-one switch that calms the body’s sugar spikes and decreases cravings. Investors watch it because regulatory approvals, clinical results, pricing and patient demand determine sales potential and competitive impact on companies in diabetes and obesity treatment markets.

real world evidence medical

"than reported in real world evidence… compared to published real world evidence"

Data about how a medical product performs in everyday use outside tightly controlled clinical trials, gathered from sources like medical records, insurance claims, patient reports, and device trackers. Investors care because this evidence can change how regulators, doctors and insurers view a product’s safety, effectiveness and value — like seeing how a car holds up on real roads versus a test track, which affects sales, approvals and reimbursement.

pharmacy claims technical

"Pharmacy claims and clinical data from a 12-month period were used"

Pharmacy claims are requests submitted to an insurer or pharmacy benefits manager asking for payment or reimbursement for a prescription drug dispensed to a patient. They act like receipts a pharmacy sends to a payer to show what was provided and how much should be covered; approval rates, processing speed, and paid amounts directly affect cash flow, revenue, patient access and cost forecasting for drug makers, insurers and healthcare investors.

clinical trial research medical

"Clinical trial research often shows outcomes under ideal conditions"

Clinical trial research is the organized testing of new medicines, medical devices or treatment methods in human volunteers to find out whether they are safe and effective. Think of it like road-testing a new car or perfecting a recipe before it goes on the menu: results determine whether a product can be approved, sold and scaled. For investors, trial outcomes and timelines drive the biggest shifts in regulatory approval, commercial potential and investment risk.

anti-obesity medications (aom) medical

"prescribing and medication management of anti-obesity medications (AOM), including GLP-1s"

Anti-obesity medications (AOM) are prescription drugs designed to help people lose weight or prevent weight gain by changing appetite, absorption, or how the body uses energy. For investors, AOMs matter because they represent a growing market and can drive revenue, partnerships, regulatory scrutiny, and healthcare cost shifts; think of them as a new appliance that can change demand across an industry, affecting manufacturers, insurers and retail channels.

AI-generated analysis. Not financial advice.

New analysis adds to existing evidence that Omada’s program paired with GLP-1 medications leads to greater weight loss and persistence than reported in real world evidence

SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced results from a 12-month real-world analysis of members in its GLP-1 companion program. By extending a previous six-month analysis, findings underscore the program’s role in helping employers manage the complexity of today’s weight loss medication market while delivering measurable, long-term value.¹

The new analysis found that members who stayed in the program and persisted on their medication for 12 months had an average weight loss of 18.4% at one year,¹ compared to 11.9% weight loss seen in real world evidence.² Among those who persisted, Omada members achieved 47% greater average weight loss on semaglutide and 37% greater weight loss on tirzepatide,¹ compared to published real world evidence.² Moreover, the analysis showed an increase in weight loss across all members in the program, including those who did and did not persist with GLP-1s for the entire year, with an average 16.3% weight loss¹ – nearly twice the amount observed in the real world analysis.²

“The promise of GLP-1s is clear: significant weight loss that unlocks broader health benefits. But that promise requires persistence through real-world challenges. As the GLP-1 landscape evolves with new access models and pricing strategies, employers need confidence that wraparound support delivers lasting value,” said Wei-Li Shao, President at Omada Health. "These outcomes demonstrate that with the right support, members can achieve the weight loss they need to improve their health. That's how behavioral support transforms medication coverage from a cost into an investment.”

The analysis followed 965 Omada members without diabetes who self-reported GLP-1 use and participated in Omada Health’s Enhanced GLP-1 Care Track, which provides resources for medication support and lifestyle change. Pharmacy claims and clinical data from a 12-month period were used to evaluate medication persistence and health outcomes among these members, all of whom had recently begun GLP-1 therapy for weight loss at program start.

For people on GLP-1s, medication persistence is known to be a key driver of a greater magnitude of weight loss.³ Results demonstrated that 67% of Omada members remained on their GLP-1 medications through one year,¹ a higher percentage than the 47-49% persistence rate in a comparable study.² Members who discontinued medication before one year achieved a 13.1% average weight loss¹ versus 6.8% among similar patients in other real world evidence.² These outcomes suggest that Omada’s program may support sustained weight loss beyond medication persistence alone.

“Long term weight health is about more than medication persistence—it's about helping each person navigate their unique journey,” said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. “By providing wraparound support at every stage, we're seeing outcomes that surpass clinical trials because we're meeting members where they are, whether starting medication, staying on it, or transitioning off while maintaining their progress.”

Omada’s Enhanced GLP-1 Care Track is designed to help members build and practice the lifestyle skills that support long-term weight health while managing side effects, working to preserve muscle mass, and navigating medication access. The program layers specialized GLP-1-focused care team support and tailored content on top of Omada’s core lifestyle curriculum, helping members optimize their medication experience.

“Clinical trial research often shows outcomes under ideal conditions — and it can be outdated by the time medications reach the market,” said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health. “At Omada, our members don’t live in lab settings. They live in the real world. That’s why we track data in real time, so we know our program is working even as medications, indications, and access evolve.”

This announcement comes on the heels of the company’s new capability of prescribing and medication management of anti-obesity medications (AOM), including GLP-1s, to tailor support before, during, and after medication treatment. The study was completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada’s behavior change weight health programs. Learn more about Omada Health’s approach to GLP-1 medications and coverage here.

About Omada Health
Omada Health (Nasdaq: OMDA) is a virtual between-visit healthcare provider that addresses cardiometabolic conditions like diabetes, hypertension, prediabetes, and obesity, as well as musculoskeletal issues. Through specialized care tracks, Omada also supports members taking GLP-1s and other anti-obesity medications. Our unique approach of Compassionate Intelligence combines human-led care teams, connected devices, and AI-powered technology to deliver personalized care at scale.

With more than a decade of experience and data, and 30 peer-reviewed publications that showcase its clinical and economic results, Omada has served over one million members since launch across more than 2,000 customers, including pharmacy benefit managers, health plans, health systems, and employers ranging in size from small businesses to Fortune 500s. Its evidence-based approach and commitment to bending the curve of chronic disease has earned the company multiple healthcare accreditations and recognition in the industry.

As a trusted partner in the healthcare ecosystem, Omada delivers measurable results that help to improve health outcomes and to manage healthcare costs. For more information, visit omadahealth.com.

Contacts
Rose Ramseth
press@omadahealth.com

Citations

1. Devaraj SM, Chang H, Napoleone JB, Linke S. Weight Health at One Year: Outcomes from Omada's Enhanced GLP-1 Care Track. Omada Health. Published January 8, 2026. Accessed January 8, 2026. https://www.omadahealth.com/resource-center/weight-health-at-one-year-outcomes-from-omadas-enhanced-glp-1-care-track
2. Gasoyan H, Butsch WS, Schulte R, et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity (Silver Spring). 2025; 33(9): 1657-1667. doi:10.1002/oby.24331
3. Chang H, Devaraj SM, Naqvi JB, Linke S. GLP-1 medication persistence, a key component of weight loss. Omada Health. Published June 17, 2025. Accessed January 2 2026. https://www.omadahealth.com/resource-center/glp-1-medication-persistence-a-key-component-of-weight-loss
   
   

FAQ

What weight loss did Omada report for members on GLP-1s after 12 months (OMDA)?

Members who persisted on medication averaged 18.4% weight loss at one year; overall program members averaged 16.3% weight loss.

How does Omada’s 12‑month GLP-1 persistence (OMDA) compare to other real‑world studies?

Omada reported 67% persistence at one year versus a 47–49% persistence rate cited in comparable real-world evidence.

How many members were included in Omada’s 12‑month GLP-1 analysis (OMDA)?

The analysis followed 965 Omada members without diabetes who self-reported GLP-1 use and joined the Enhanced GLP-1 Care Track.

What data sources did Omada use in the 12‑month GLP-1 analysis (OMDA)?

The study used pharmacy claims and clinical data over a 12-month period to evaluate medication persistence and weight outcomes.

Does Omada prescribe and manage GLP-1 medications as part of its program (OMDA)?

Yes. The company announced new capabilities for prescribing and medication management of anti-obesity medications, including GLP-1s.